ritonavir
ritonavir: developed by 1 company · 5 clinical trials tracked · 2 FDA decisions.
ritonavir evidence translation
What we can confirm
2 FDA records · 5 tracked trials
What it means
What to watch
Prepared research question
How could ritonavir → ABBV affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| AbbVie Inc. (ABBV) | Approved |
Clinical Trials (5)
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303/BNT323 in Patients With Advanced/Metastatic Solid Tumors
Primary endpoint: Phase 1: Percentage of Participants with Dose-Limiting Toxicities (DLTs) as assessed by CTCAE v5.0.
Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum
Primary endpoint: Number of Women Who Meet Area Under the Curve (AUC) Target in Plasma (Component 1)
Once Daily (QD) Dosing of Lonafarnib (LNF) Co-administered With Ritonavir (RTV) for Treatment of Chronic Hepatitis D Virus Infection
Primary endpoint: Viral load change
Pilot Study to Measure Exposure to Atazanavir, as a Component of Pharmacokinetic Parameters and Adherence Measured With MEMS in Naive HIV-infected Patients Treated Once Daily With Atazanavir Combined to Ritonavir and to Tenofovir/Emtricitabine. ANRS 134 Cophar 3
Primary endpoint: pharmacokinetic parameters of atazanavir (ATV) when combined with ritonavir (RTV) and tenofovir/emtricitabine
A Randomized Multicenter Study With Non-inferiority Hypothesis, Comparing the Availability to Maintain a Complete Viral Suppression by a Monotherapy of Darunavir/r to a NRTI Containing Regimen Including Darunavir/r, in HIV-1 Infected Patients With Previous Prolonged Complete Viral Suppression. ANRS 136 MONOI
Primary endpoint: Proportion of patients with virological success, the virological failure is defined as 2 consecutive plasma viral load measurements greater or equal to 400 cp/ml within 2 weeks at W48
FDA Decisions2 records
Frequently asked questions
Who is developing ritonavir?
ritonavir is being developed by AbbVie Inc..
How many clinical trials involve ritonavir?
BioSniper tracks 5 clinical trials involving ritonavir.
What is ritonavir's latest FDA decision?
The most recent tracked FDA decision for ritonavir is Approval, dated June 7, 2017.